ROBIT PLC PUBLISHES HALF-YEAR REPORT FOR JANUARY-JUNE 2022 ON 9 AUGUST 2022 AT 11 A.M. EEST
ROBIT PLC PRESS RELEASE 26 JULY 2022 AT 11.00 A.M.
ROBIT PLC PUBLISHES HALF-YEAR REPORT FOR JANUARY-JUNE 2022 ON 9AUGUST 2022 AT 11A.M. EEST
Robit Plc will publish its half-year financial report for January-June 2022 on Tuesday 9 August 2022 at 11.00 a.m. EEST. The report and related presentation material will be available on the company’s website at https://www.robitgroup.com/investor/financial-information/ after publishing.
Analyst, investor, and press conference
A press conference for analysts, investors and media will be held on Tuesday 9 August 2022 at 2.00 p.m. EEST. The conference will take place in Helsinki at Scandic Simonkenttä (meeting room Mansku), Simonkatu 9, FI-00100 Helsinki. Doors will be open at 1.30 p.m. EEST. The conference will be held in English.
The report will be presented by Robit Plc’s Group CEO, Arto Halonen and Interim CFO, Ville Peltonen.
Pre-registrations to the press conference by Friday 5 August 2022 at 10.00 a.m. EEST via email investors@robitgroup.com.
The conference can also be viewed as a live webcast at https://www.31415.fi/r15022022 or alternatively https://www.3141.fi/r15022022. Registration is not required.
The webcast will be recorded. The recording will be available on the company’s website at https://www.robitgroup.com/investor/financial-information/ after the press conference.
Silent period
The silent period preceding the publication is ongoing and continues until the disclosure.
ROBIT PLC
Arto Halonen
Further information:
Robit Plc
Arto Halonen, CEO
+358 40 028 0717
arto.halonen@robitgroup.com
Distribution:
Nasdaq Helsinki Ltd
Key media
www.robitgroup.com
Robit is a strongly internationalized growth company servicing global customers and selling drilling consumables for applications in mining, construction, geotechnical engineering and well drilling. The company’s offering is divided into three product and service ranges: Top Hammer, Down the Hole and Geotechnical. Robit has sales and service points in 9 countries as well as an active sales network in more than 100 countries. Robit’s manufacturing units are located in Finland, South Korea, Australia and the UK. Robit’s shares are listed on Nasdaq Helsinki Ltd. Further information is available at www.robitgroup.com.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Borregaard ASA: EBITDA1 of NOK 442 million in the 1st quarter24.4.2024 07:00:00 CEST | Press release
Borregaard’s operating revenues reached NOK 1,975 million (NOK 1,850 million)2 in the 1st quarter of 2024. EBITDA1 increased to NOK 442 million (NOK 435 million). The result in BioSolutions increased while results in BioMaterials and Fine Chemicals were lower compared with the 1st quarter of 2023. The result in BioSolutions increased due to higher sales volume and reduced energy costs. In BioMaterials, higher sales volume was more than offset by lower sales prices and higher wood costs. Fine Chemicals had a lower result due to low bioethanol deliveries and increased costs. The net currency effects were slightly negative for the Group. Profit before tax was NOK 261 million (NOK 292 million). Earnings per share were NOK 2.01 (NOK 2.32). - We are pleased with the strong result improvement in BioSolutions and the positive sales volume development for the Group, says President and CEO Per A. Sørlie. Contacts: Director Investor Relations, Knut-Harald Bakke, +47 905 79 164 Director Communicat
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-1924.4.2024 07:00:00 CEST | Press release
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appratioss fn of the Swiranc against most currencies, sales were 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A). Divisional sales growth was 2%, reflecting the impact of the expected decline in sales of the COVID-19 medicine Ronapreve Diagnostics Division base business2 grew by 8%, supported by growth across all regions because of demand for immunodiagnostic products, clinical chemistry tests and advanced staining solutions. As this growth was partially offset by the lower dem
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates24.4.2024 07:00:00 CEST | Press release
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date are consistent with previously announced topline data observing no statistically significant or clinically meaningful effect of varoglutamstat on cognition and function in early AD up to 600mg twice a day (BID) doseStatistically significant improvement in kidney function observed with varoglutamstat 600mg BID in VIVIAD over two years based on pre-specified analysis of the estimated glomerular filtration rateCompany plans to explore potential of varoglutamstat in kidney disease in a shift of strategic focus towards inflammatory and fibrotic disorders VIVA-MIND Phase 2 study to be discontinued early, in H2 2024, which will enable accelerated data analysis and inform varoglutamstat development strategyCompany is taking steps to reduce cash utilizatio
Wereldhave Trading update Q1 202424.4.2024 07:00:00 CEST | Press release
Full Service Center footfall continues to power ahead: 10% above Q1 2023Retail sales +5%, well above inflationPolarizing leasing market in the Benelux with several expanding formulas but also some bankruptciesLeasing spreads in the Netherlands moving into positive territoryRent collection >97% underpinning tenant qualityLTV improved to 41.5% due to positive Belgian revaluations (ERV driven) and targeted CAPEXUpdate on short-term strategic focus: rotating capital out of the Netherlands to further reduce LTVFull Service Center Sterrenburg awarded with the 2024 Kern annual development awardForecast FY 2024 DRPS € 1.75 reiterated Attachment Trading update Q1 2024 Wereldhave N.V.
IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma24.4.2024 07:00:00 CEST | Press release
ROTTERDAM, The Netherlands 24 April 2024 – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Spain has signed an agreement to acquire 100% of the shares in Cobapharma, S.L.U, a European distributor in the pharmaceutical and nutraceutical industry. Established in 2011 and headquartered in Barcelona, Spain, Cobapharma provides an extensive portfolio of Active Pharmaceutical Ingredients (APIs) as well as nutraceutical ingredients. With 20 employees, Cobapharma represents leading suppliers and generated a revenue of approximately EUR 19 million in the financial year that ended December 31, 2023. ‘Cobapharma is a rapidly growing distributor in the pharmaceutical and nutraceutical industry. Their esteemed reputation for providing high-quality APIs and nutraceutical ingredients perfectly complements our existing portfolio. The alignment of our business models will enhance our ability to serve our customers and partners’ c